Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the impact of recent clinical trials focused on genetic mutations and whether they are impacting the way we treat prostate cancer patients

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, provides perspective on the IPATential150 study in metastatic castration-resistant prostate cancer (mCRPC) presented at the 2020 ESMO Virtual Congress ESMO20

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, shares thoughts on the TROPHY-U-01 clinical study investigating sacituzumab govitecan in patients with locally advanced/unresectable or metastatic urothelial carcinoma (mUC)

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the CheckMate 9ER clinical trial investigating the combination of nivolumab plus cabozantinib in the first-line treatment of advanced renal cell carcinoma (RCC) presented at the 2020 ESMO Virtual Congress

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, offers opinion on whether the results of CheckMate 9ER are practice-changing and how the nivolumab plus cabozantinib regimen fits in among other immuno-oncology (I-O) regimens for the first-line treatment of advanced renal cell carcinoma (RCC)

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, considers whether certain patient subtypes are more likely to respond when administering nivolumab plus cabozantinib in the first-line renal cell carcinoma (RCC) setting

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tells us about the outcomes of the PROfound study and whether medical oncologists should consider olaparib in the management of their metastatic castration-resistant prostate cancer (mCRPC) patients

Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, tells us about the outcomes of the PROfound study and considers whether medical oncologists should include olaparib in the management of their metastatic castration-resistant prostate cancer (mCRPC) patients

Dr. Galsky, Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director, Center of Excellence for Bladder Cancer, The Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, considers the implications of the IMvigor130 clinical study and whether atezolizumab should be combined with chemotherapy in the treatment of first-line bladder cancer

Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, considers how treatment algorithms for metastatic castration-resistant prostate cancer (mCRPC) have changed as a result of recent clinical trial outcomes (i.e. PROfound and CARD)

Dr. Kato, Specialist, Clinical Oncology, National Cancer Center Hospital, Tokyo, Japan, discusses the role of PD-L1 biomarkers in determining treatment decisions in esophageal cancer

Dr. Galsky, Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director, Center of Excellence for Bladder Cancer, The Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, tells us about the outcomes of the PROfound study whether medical oncologists should olaparib in the management of their metastatic castration-resistant prostate cancer (mCRPC) patients

Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, speculates on how recent clinical trials focused on genetic mutations impact the way advanced prostate cancer is treated

Dr. Kato, Specialist, Clinical Oncology, National Cancer Center Hospital, Tokyo, Japan, shares the design and outcomes of the Keynote-590 trial investigating pembrolizumab in locally advanced or first-line metastatic esophageal cancer presented at the 2020 ESMO Virtual Congress

Dr. Galsky, Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director, Center of Excellence for Bladder Cancer, The Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, explains how recent clinical studies focused on genetic mutations are influencing the way advanced prostate cancer is treated

Dr. Galsky, Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director, Center of Excellence for Bladder Cancer, The Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, discusses the TROPHY-U-01 study investigating sacituzumab govitecan in patients with unresectable, locally advanced or metastatic urothelial carcinoma (mUC) presented at the 2020 ESMO Virtual Congress

Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, shares impressions of the post-hoc analysis of the ARCHES study investigating the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) presented at the 2020 ESMO Virtual Congress

Dr. Kato, Specialist, Clinical Oncology, National Cancer Center Hospital, Tokyo, Japan, considers key takeaways from the Keynote-590 clinical trial regarding the treatment of adenocarcinoma versus squamous cell carcinoma in locally advanced or first-line metastatic esophageal cancer

Dr. Galsky, Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director, Center of Excellence for Bladder Cancer, The Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, provides perspective on the outcomes of the CheckMate-274 study investigating nivolumab as adjuvant therapy for high risk, muscle-invasive urothelial carcinoma

Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, discusses the long-term overall survival analysis of the IMpassion-130 clinical trial investigating the atezolizumab and nab paclitaxel combination in triple negative metastatic breast cancer (TNBC) patients presented at the 2020 ESMO Virtual Congress